Preclinical study suggests new approach to reduce COVID-19 death among the elderly

New research from the University of Minnesota Medical School and colleagues at the Mayo Clinic reveals a possible new approach to preventing death and severe disease in elderly people infected with SARS-CoV-2. The researchers demonstrated in a preclinical study that senolytic drugs significantly reduced mortality upon infection from a beta-coronavirus closely related to SARS-CoV-2 in older mice. The study published […]

Read more

Researchers test novel gene regulation approach to treat brain diseases

Researchers at the DZNE (Germany), at Massachusetts General Hospital (USA) and at the genomic medicine company Sangamo Therapeutics, Inc. tested a novel gene regulation approach to treat brain diseases such as Alzheimer's in laboratory studies. It leverages zinc finger proteins, which specifically bind to the DNA that codes for the protein Tau without altering it, thereby reducing Tau production in […]

Read more

4th preclinical study for Novavax in non-human primates, tests SARS-CoV-2 variants

Researchers in the United States have identified specific immune correlates that might be key to ensuring that vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protects against not only disease but also viral transmission and emerging variants. The SARS-CoV-2 virus is the agent responsible for the coronavirus disease (COVID-19) pandemic that has claimed the lives of more than 2.32 […]

Read more

Drug combination shows promise in preclinical models of triple negative breast cancer

Tumor volume in a preclinical model of triple negative breast cancer (TNBC) was reduced four times more when an experimental polo-like kinase 1 (PLK1) inhibitor was combined with a standard-of-care chemotherapeutic agent than when the agent was used alone. Hollings Cancer Center scientists at the Medical University of South Carolina reported these findings in PLOS ONE. TNBC disproportionately affects African […]

Read more

Scientists reverse fibrosis in preclinical studies

In cell and mouse models, Mayo Clinic researchers and collaborators have identified a way to slow and reverse the process of uncontrolled internal scarring, called fibrosis. This disease process has few effective therapies, no cure and can be fatal when it occurs in organs such as the liver (cirrhosis) or lungs (pulmonary fibrosis). The findings appear Wednesday, Oct. 30, in […]

Read more